The emergence of a new class of antibiotics promises to reshape our battle against antibiotic resistance, particularly in the face of rapidly evolving drug-resistant bacteria.Kinvard Bio, a groundbreaking biotech startup emerging from Harvard University, is at the forefront of this innovation, bringing hope to a public health crisis that claims millions of lives annually.